Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
Authors:
- 29 October 2021
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (12) , 5148-5149
Abstract
Vaccines against SARS-CoV-2 are known to be less immunogenic for some individuals, whereas others present notably high levels of antibody production. We assessed the cellular response to BNT162b2 among individuals with low post-vaccination antibody levels as well as in a small group of individuals with high titers. Antibody levels were assessed by the Abbott SARS-CoV-2 IgG II Quant assay. The interferon-γ production of T-cells in response to SARS-CoV-2 antigens was determined using Qiagen’s QuantiFERON SARS-CoV-2 ELISA test. Our results showed that participants with high antibody levels presented adequate cellular response in all studied cases, whereas those with low antibody levels generally showed limited to almost absent cellular response five months post vaccination.Keywords
Funding Information
- No funding
This publication has 10 references indexed in Scilit:
- Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipientsAmerican Journal of Transplantation, 2022
- The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responsesClinical Microbiology and Infection, 2021
- The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysisKidney International, 2021
- Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory diseaseAnnals of the Rheumatic Diseases, 2021
- Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)Clinical Microbiology and Infection, 2021
- Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated IndividualsInfectious Diseases and Therapy, 2021
- Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, GermanyEmerging Infectious Diseases, 2021
- Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaBlood, 2021
- Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home ResidentsClinical Infectious Diseases, 2021
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variantsNature, 2021